Skip to content
Bending the Curve Trial by Trial
?

Back to Prostate cancer

References: Prostate cancer

169 sources cited on this page. Links open the primary source.

  1. Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. Bull Johns Hopkins Hosp. 1905;16(175):315-321. Source
    CiteLoading…
  2. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-8. PubMed
    CiteLoading…
  3. Nobel Foundation. Charles B. Huggins - Biographical. From Nobel Lectures, Physiology or Medicine 1963-1970, Elsevier Publishing Company, Amsterdam, 1972. NobelPrize.org. Web page read 2026-10-20. Source
  4. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17(2):159-63. PubMed
    CiteLoading…
  5. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982;79(5):1658-62. PubMedDOI
    CiteLoading…
  6. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128(3):492-7. PubMedDOI
    CiteLoading…
  7. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4(5):473-85. PubMedDOI
    CiteLoading…
  8. US Food and Drug Administration. Hybritech, Inc.; Premarket Approval of Tandem-R PSA Immunoradiometric Assay for the Quantitative Measurement of Prostate-Specific Antigen (PSA) in Serum; notice (Docket No. 86M-0137). Fed Regist. 1986 Apr 9;51(68):12211-12212 (FR Doc. 86-7827). Source
  9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16. PubMedDOI
    CiteLoading…
  10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-61. PubMedDOI
    CiteLoading…
  11. US Food and Drug Administration. Hybritech, Inc.; Premarket Approval of Tandem-R, E, and ERA PSA Assays; notice (Docket No. 94M-0327). Fed Regist. 1994 Oct 14;59(198) (FR Doc. 94-25516). Source
  12. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300. PubMedDOI
    CiteLoading…
  13. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-6. PubMedDOI
    CiteLoading…
  14. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781-9. PubMedDOI
    CiteLoading…
  15. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9-12. Originally published in Cancer Res. 1941;1:293-297. PubMedDOI
    CiteLoading…
  16. US Food and Drug Administration. Supplemental NDA approval letter, Taxotere (docetaxel), NDA 20-449/S-028, Aventis Pharmaceuticals; electronic signature dated 5/19/04. Source
  17. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20. PubMedDOI
    CiteLoading…
  18. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12. PubMedDOI
    CiteLoading…
  19. Androutsos G. Carcinoma of the prostate. A historical account. J BUON. 2005;10(1):135-44. PubMedSource
    CiteLoading…
  20. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977-84. PubMedDOI
    CiteLoading…
  21. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5. PubMedDOI
    CiteLoading…
  22. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289-95. PubMedDOI
    CiteLoading…
  23. US Food and Drug Administration. NDA approval letter, degarelix for injection, NDA 22-201, Ferring Pharmaceuticals; electronic signature dated 12/24/2008. Source
  24. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-91. PubMedDOI
    CiteLoading…
  25. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9. PubMedDOI
    CiteLoading…
  26. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8. PubMedDOI
    CiteLoading…
  27. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066-73. PubMedDOI
    CiteLoading…
  28. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54. PubMedDOI
    CiteLoading…
  29. US Food and Drug Administration. NDA approval letter, Jevtana (cabazitaxel) injection, NDA 201023, sanofi-aventis U.S.; electronic signature dated 06/17/2010. Source
  30. US Food and Drug Administration, Center for Biologics Evaluation and Research. PROVENGE (sipuleucel-T), STN BL 125197: product page (indication wording) and approval-history file containing the Office Director memo 'Indication Statement' dated April 29, 2010. Page content current as of 05/28/2019; read 2026-10-20. Source
  31. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-32. PubMedDOI
    CiteLoading…
  32. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22. PubMedDOI
    CiteLoading…
  33. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-31. PubMedDOI
    CiteLoading…
  34. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-17. PubMedDOI
    CiteLoading…
  35. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005. PubMedDOI
    CiteLoading…
  36. US Food and Drug Administration. NDA approval letter, Zytiga (abiraterone acetate) tablets, NDA 202379, Ortho Biotech Oncology Research and Development (Cougar Biotechnology); electronic signature dated 04/28/2011. Source
  37. US Food and Drug Administration. NDA approval letter, Xtandi (enzalutamide) capsules, NDA 203415, Medivation, Inc.; electronic signature dated 08/31/2012. Source
  38. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92. PubMedDOI
    CiteLoading…
  39. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34. PubMedDOI
    CiteLoading…
  40. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97. PubMedDOI
    CiteLoading…
  41. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-90. PubMedDOI
    CiteLoading…
  42. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-13. PubMedDOI
    CiteLoading…
  43. FDA. Approval letter, NDA 203971 (Xofigo, radium Ra 223 dichloride injection), signed 15 May 2013. Source
  44. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149-58. PubMedDOI
    CiteLoading…
  45. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. PubMedDOI
    CiteLoading…
  46. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-42. PubMedDOI
    CiteLoading…
  47. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-35. PubMedDOI
    CiteLoading…
  48. European Medicines Agency. Provenge (sipuleucel-T): European public assessment report page (marketing authorisation issued 06/09/2013; withdrawal 06/05/2015). Page read 2026-10-20. Source
  49. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272-7. PubMedDOI
    CiteLoading…
  50. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46. PubMedDOI
    CiteLoading…
  51. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047-1060. PubMedDOI
    CiteLoading…
  52. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016;375(15):1425-1437. PubMedDOI
    CiteLoading…
  53. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-52. PubMedDOI
    CiteLoading…
  54. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415-1424. PubMedDOI
    CiteLoading…
  55. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. PubMedDOI
    CiteLoading…
  56. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443-53. PubMedDOI
    CiteLoading…
  57. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. PubMedDOI
    CiteLoading…
  58. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017;35(17):1884-1890. PubMedDOI
    CiteLoading…
  59. Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198-3206. PubMedDOI
    CiteLoading…
  60. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360. PubMedDOI
    CiteLoading…
  61. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338-351. PubMedDOI
    CiteLoading…
  62. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592-599. PubMedDOI
    CiteLoading…
  63. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017;167(7):449-455. PubMedDOI
    CiteLoading…
  64. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377(2):132-142. PubMedDOI
    CiteLoading…
  65. Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018;379(24):2319-2329. PubMedDOI
    CiteLoading…
  66. US Food and Drug Administration. Erleada (apalutamide) tablets, prescribing information, initial U.S. approval 2018 (revised 02/2018), NDA 210951, Drugs@FDA label file 210951s000lbl.pdf. Accessed 20 October 2026. Source
  67. US Food and Drug Administration. Replacement NDA approval letter, Erleada (apalutamide) tablets, NDA 210951, Janssen Biotech, Inc.; signed 02/14/2018 (effective approval date stated as 14 February 2018, the date of the original approval letter). Source
  68. US Food and Drug Administration. Supplemental NDA approval letter, Xtandi (enzalutamide) capsules, NDA 203415/S-014, Astellas; electronic signature dated 07/13/2018. Source
  69. US Food and Drug Administration. Replacement supplemental NDA approval letter, Zytiga (abiraterone acetate), NDA 202379/S-024; signed 02/07/2018 (effective approval date stated as 7 February 2018, the date of the original approval letter). Source
  70. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465-2474. PubMedDOI
    CiteLoading…
  71. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-1777. PubMedDOI
    CiteLoading…
  72. Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018;319(9):883-895. PubMedDOI
    CiteLoading…
  73. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378(15):1408-1418. PubMedDOI
    CiteLoading…
  74. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901-1913. PubMedDOI
    CiteLoading…
  75. US Preventive Services Task Force. Prostate Cancer: Screening (recommendation page; final recommendation statement published 8 May 2018; page states the topic is being updated). Accessed 20 October 2026. Source
  76. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974-2986. PubMedDOI
    CiteLoading…
  77. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13-24. PubMedDOI
    CiteLoading…
  78. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121-131. PubMedDOI
    CiteLoading…
  79. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381(26):2506-2518. PubMedDOI
    CiteLoading…
  80. US Food and Drug Administration. Supplemental NDA approval letter, Erleada (apalutamide), NDA 210951/S-001, Janssen Biotech, Inc.; electronic signature dated 09/17/2019. Source
  81. US Food and Drug Administration. NDA approval letter, Nubeqa (darolutamide) tablets, NDA 212099, Bayer HealthCare; electronic signature dated 07/30/2019. Source
  82. US Food and Drug Administration. Supplemental NDA approval letter, Xtandi (enzalutamide) capsules, NDA 203415/S-015, Astellas; electronic signature dated 12/16/2019. Source
  83. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686-700. PubMedDOI
    CiteLoading…
  84. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(13):1235-1246. PubMedDOI
    CiteLoading…
  85. Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43-51. PubMedDOI
    CiteLoading…
  86. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385-395. PubMedDOI
    CiteLoading…
  87. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020;38(32):3763-3772. PubMedDOI
    CiteLoading…
  88. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-2102. PubMedDOI
    CiteLoading…
  89. FDA. Supplement approval letter, NDA 208558/S-016 (Lynparza, olaparib; companion diagnostic for ATM, BRCA1 and BRCA2 in mCRPC), signed 7 December 2020. Source
  90. FDA. Supplement approval letter, NDA 208558/S-014 (Lynparza, olaparib; HRR gene-mutated mCRPC), signed 19 May 2020. Source
  91. FDA. Accelerated approval letter, NDA 209115/S-004 (Rubraca, rucaparib; BRCA-mutated mCRPC), signed 15 May 2020. Source
  92. US Food and Drug Administration. NDA approval letter, Orgovyx (relugolix) tablets, NDA 214621, Myovant Sciences; electronic signature dated 12/18/2020. Source
  93. US Food and Drug Administration. Approval letter, NDA 212642, PSMA-11 Ga 68 Injection, University of California Los Angeles; electronic signature dated 1 December 2020. Source
  94. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020;383(11):1040-1049. PubMedDOI
    CiteLoading…
  95. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. PubMedDOI
    CiteLoading…
  96. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;383(24):2345-2357. PubMedDOI
    CiteLoading…
  97. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020;382(23):2187-2196. PubMedDOI
    CiteLoading…
  98. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(23):2197-2206. PubMedDOI
    CiteLoading…
  99. Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021;39(20):2294-2303. PubMedDOI
    CiteLoading…
  100. Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N Engl J Med. 2021;385(10):908-920. PubMedDOI
    CiteLoading…
  101. US Food and Drug Administration. Approval letter, NDA 214032, ILLUCCIX (kit for the preparation of gallium Ga 68 gozetotide injection), Telix Pharmaceutical, Inc.; electronic signature dated 17 December 2021. Source
  102. US Food and Drug Administration. Approval letter, NDA 214793, PYLARIFY (piflufolastat F 18 injection); electronic signature dated 26 May 2021. Source
  103. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804. PubMedDOI
    CiteLoading…
  104. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. PubMedDOI
    CiteLoading…
  105. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021;79(1):150-158. PubMedDOI
    CiteLoading…
  106. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022;40(15):1616-1622. PubMedDOI
    CiteLoading…
  107. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022;1(9):EVIDoa2200043. PubMedDOI
    CiteLoading…
  108. FDA. Approval letter, NDA 215833 (Pluvicto, lutetium Lu 177 vipivotide tetraxetan), signed 23 March 2022. Source
  109. US Food and Drug Administration. Supplemental NDA approval letter, Nubeqa (darolutamide) tablets, NDA 212099/S-002, Bayer HealthCare; electronic signature dated 08/05/2022. Source
  110. US Food and Drug Administration. Approval letter, NDA 215841, LOCAMETZ (kit for the preparation of gallium Ga 68 gozetotide injection), Advanced Accelerator Applications USA, Inc.; electronic signature dated 23 March 2022. Source
  111. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695-1707. PubMedDOI
    CiteLoading…
  112. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132-1142. PubMedDOI
    CiteLoading…
  113. Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308-1320. PubMedDOI
    CiteLoading…
  114. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291-303. PubMedDOI
    CiteLoading…
  115. Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443-456. PubMedDOI
    CiteLoading…
  116. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41(18):3339-3351. PubMedDOI
    CiteLoading…
  117. Donovan JL, Hamdy FC, Lane JA, Young GJ, Metcalfe C, Walsh EI, et al. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. NEJM Evid. 2023;2(4):EVIDoa2300018. PubMedDOI
    CiteLoading…
  118. FDA. Approval letter, NDA 216793 (Akeega, niraparib/abiraterone acetate fixed-dose combination; BRCA-mutated mCRPC), signed 11 August 2023. Source
  119. FDA. Supplement approval letter, NDA 208558/S-025 (Lynparza with abiraterone and prednisone or prednisolone; BRCA-mutated mCRPC), signed 31 May 2023. Source
  120. FDA. Supplement approval letter, NDA 211651/S-010 (Talzenna with enzalutamide; HRR gene-mutated mCRPC), signed 20 June 2023. Source
  121. US Food and Drug Administration. Approval letter, NDA 216023, Posluma (flotufolastat F 18) injection, Blue Earth Diagnostics Ltd.; electronic signature dated 25 May 2023. Source
  122. US Food and Drug Administration. Supplemental NDA approval letter, Xtandi (enzalutamide) capsules and tablets, NDA 203415/S-022 and NDA 213674/S-010, Astellas Pharma US, Inc.; electronic signature dated 11/16/2023. Source
  123. Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388(8):719-732. PubMedDOI
    CiteLoading…
  124. Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389(16):1453-1465. PubMedDOI
    CiteLoading…
  125. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMedDOI
    CiteLoading…
  126. Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094-1108. PubMedDOI
    CiteLoading…
  127. Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323-334. PubMedDOI
    CiteLoading…
  128. Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, et al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331(17):1452-1459. PubMedDOI
    CiteLoading…
  129. Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99-107. PubMedDOI
    CiteLoading…
  130. Hugosson J, Godtman RA, Wallstrom J, Axcrona U, Bergh A, Egevad L, et al. Results after Four Years of Screening for Prostate Cancer with PSA and MRI. N Engl J Med. 2024;391(12):1083-1095. PubMedDOI
    CiteLoading…
  131. Martin RM, Turner EL, Young GJ, Metcalfe C, Walsh EI, Lane JA, et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. JAMA. 2024;331(17):1460-1470. PubMedDOI
    CiteLoading…
  132. Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. PubMedDOI
    CiteLoading…
  133. Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024;42(36):4271-4281. PubMedDOI
    CiteLoading…
  134. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):447-460. PubMedDOI
    CiteLoading…
  135. Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025;31(12):4109-4118. PubMedDOI
    CiteLoading…
  136. Belisario YG, van Leenders GJLH. Current grading of prostate cancer. Pathologie (Heidelb). 2025;46(Suppl 1):10-15. PubMedDOI
    CiteLoading…
  137. Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, et al. Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. Eur Urol Oncol. 2025;8(4):986-998. PubMedDOI
    CiteLoading…
  138. FDA. Supplement approval letter, NDA 216793/S-001 (Akeega with prednisone; BRCA2-mutated metastatic castration-sensitive prostate cancer), signed 12 December 2025. Source
  139. FDA. FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. Notice, 12 December 2025. Source
  140. FDA. Supplement approval letter, NDA 215833/S-021 and S-024 (Pluvicto), signed 28 March 2025. Source
  141. FDA. FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication. Notice, 28 March 2025. Source
  142. FDA. Supplement approval and fulfillment of postmarketing requirement letter, NDA 209115/S-014 and S-015 (Rubraca, rucaparib), signed 17 December 2025. Source
  143. FDA. FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer. Notice, 17 December 2025. Source
  144. US Food and Drug Administration. Supplemental NDA approval letter, Nubeqa (darolutamide) tablets, NDA 212099/S-008, Bayer HealthCare; electronic signature dated 06/03/2025. Source
  145. Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36(11):1319-1330. PubMedDOI
    CiteLoading…
  146. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):461-474. PubMedDOI
    CiteLoading…
  147. Roobol MJ, de Vos II, Månsson M, Godtman RA, Talala KM, den Hond E, et al. European Study of Prostate Cancer Screening - 23-Year Follow-up. N Engl J Med. 2025;393(17):1669-1680. PubMedDOI
    CiteLoading…
  148. Cornford P, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2026;90(3):254-269. PubMedDOI
  149. Cancer Research UK. Prostate cancer survival statistics. Health professional page. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/survival. Page accessed 20 October 2026; no update date seen in the page text. Source
  150. ClinicalTrials.gov. NCT02952534 (TRITON2). Registry record, accessed 20 October 2026. NCT02952534
  151. ClinicalTrials.gov. NCT04136353 (DASL-HiCaP, ANZUP1801). Registry record, API v2, accessed 20 October 2026. NCT04136353
  152. ClinicalTrials.gov. NCT05939414 (PSMA-DC). Registry record, API v2, accessed 20 October 2026. NCT05939414
  153. ClinicalTrials.gov. NCT06120491 (EvoPAR-Prostate01). Registry record, API v2, accessed 20 October 2026. NCT06120491
  154. ClinicalTrials.gov. NCT06136624 (OMAHA-003, MK-5684-003). Registry record, API v2, accessed 20 October 2026. NCT06136624
  155. ClinicalTrials.gov. NCT06320067 (STAMPEDE2). Registry record, API v2, accessed 20 October 2026. NCT06320067
  156. ClinicalTrials.gov. NCT06551324 (MEVPRO-1). Registry record, API v2, accessed 20 October 2026. NCT06551324
  157. EMA. Pluvicto (lutetium (177Lu) vipivotide tetraxetan): European public assessment report page, accessed 20 October 2026. Source
  158. EMA. Xofigo (radium-223 dichloride): European public assessment report page, accessed 20 October 2026. Source
  159. FDA. Supplement approval letter, NDA 215833/S-037 (Pluvicto), signed 31 July 2026. The first page of the PDF is an image; the signature date and postmarketing commitment text were read. Source
  160. FDA. FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Notice, approval 31 July 2026 (content current as of 3 August 2026). Source
  161. FDA. Supplement approval letter, NDA 218197/S-004 (Truqap, capivasertib, with abiraterone and prednisone; PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer), signed 12 June 2026. Source
  162. FDA. FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer. Notice, approval 12 June 2026. Source
  163. Fizazi K, Attard G, Azad AA, Baciarello G, Beltran H, Bjartell A, et al. Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(5):590-607. PubMedDOI
  164. Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53-68. PubMedDOI
    CiteLoading…
  165. NobelPrize.org. Charles B. Huggins - Facts. The Nobel Prize in Physiology or Medicine 1966. Nobel Prize Outreach. Web page read 2026-10-20. Source
  166. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Prostate Cancer. Page accessed 20 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Source
  167. Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, et al. [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026;408(10557):793-807. PubMedDOI
    CiteLoading…
  168. Tilki D, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2026;90(3):270-290. PubMedDOI
  169. Walz J, Attard G, Bjartell A, Blanchard P, Castro E, Compérat E, et al. Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(4):453-469. PubMedDOI